Drug Profile
Fimasartan/linagliptin - Boryung Pharmaceutical
Alternative Names: Linagliptin/fimasartan - Boryung PharmaceuticalLatest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator Boryung Pharmaceutical
- Class Alkynes; Antihyperglycaemics; Antihypertensives; Piperidines; Purines; Pyrimidinones; Quinazolines; Small molecules
- Mechanism of Action Angiotensin type 1 receptor antagonists; Dipeptidyl peptidase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetes mellitus; Hypertension
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for phase-I development in Diabetes-mellitus(In volunteers) in South Korea (PO)
- 28 Aug 2021 No recent reports of development identified for phase-I development in Hypertension(In volunteers) in South Korea (PO)
- 30 Jun 2019 Boryung Pharmaceutical completes a phase I trial in Hypertension and Diabetes mellitus (In volunteers) in South Korea (PO) (NCT03609294)